



---

## Worldwide Pharmaceutical Operations

18<sup>th</sup> June 2008

Dr Carole Longson  
Director  
Centre for Health Technology Evaluation  
National Institute for Health and Clinical Excellence  
MidCity Place  
71 High Holborn  
London WC1V 6NA

Dear Dr Longson

**Health Technology Appraisal  
Bevacizumab, sorafenib, sunitinib and temsirolimus for renal cell carcinoma**

Thank you for allowing Pfizer the opportunity to comment on the Assessment Report for the above appraisal.

Pfizer believe that the although the approach taken by the Assessment Group appears reasonably objective overall. Aspects of the approach and a number of the assumptions they have made serve to diminish the estimated value that Sutent can bring in improving both the quality of life and the survival of patients with metastatic renal cell carcinoma, as well as seriously distorting the cost-effectiveness of Sutent.

Attached are our comments in detail.

Yours sincerely

[Redacted signature]

Direct Line: [Redacted phone number]

Enc